mometasone-furoate and Alopecia-Areata

Alopecia areata (AA) is an immune-mediated disease that targets anagen hair follicles. Despite various therapeutic options, there is no cure for AA. Prostaglandin analogues have been recognized as being capable of inducing hypertrichosis.. To compare the efficacy and safety of bimatoprost to those of corticosteroid in the treatment of scalp AA.. Thirty adult patients with patchy AA (S1) were included. Two AA patches were randomly assigned to treatment either by mometasone furoate 0.1% cream once daily (area A) or bimatoprost 0.03% solution twice daily (area B) for 3 months. Patients were assessed using the Severity of Alopecia Tool (SALT) scoring system for hair re-growth.. All responding AA patches showed significant reduction in their SALT score after therapy. Area B demonstrated significantly better results regarding rapidity of response in weeks, percentage of hair re-growth and side effects compared to area A.. Bimatoprost solution represents a therapeutic option for scalp AA.

Topics: Administration, Cutaneous; Adult; Alopecia Areata; Bimatoprost; Dermatologic Agents; Female; Hair; Humans; Male; Middle Aged; Mometasone Furoate; Pilot Projects; Prospective Studies; Scalp; Severity of Illness Index; Single-Blind Method; Skin Cream; Young Adult

Alopecia areata (AA) is an autoimmune disease characterized by non-cicatricial hair loss. No definitive therapy currently exists for AA. To compared the efficacy and safety of the mometasone furoate 0.1% cream alone with the mometasone furoate 0.1% cream plus adapalene 0.1% gel in treatment of AA. Twenty patients with AA and with mean age of 27.4 ± 9.2 years were enrolled. Patches with a diameter of < 5 cm were treated with mometasone furate 0.1% cream (M), and patches with a diameter of ≥5 cm were treated with mometasone furate 0.1% cream plus adapalene 0.1% gel (M + D) for a period of 12 weeks. Hair regrowth was evaluated using a Re-growth score (RGS). Mean RGSs of M + D group were higher than M group for 4th week (2.60 vs. 1.45); 8th week (3.85 vs. 2.40) and 12th week (4.40 vs. 3.30). Mean percentages of hair re-growth in M + D group were statistically higher than M group for 4th (50.2% vs. 23.5%), 8th (78.5% vs. 50.7%), and 12th week (90.5% vs. 71%). Study revealed the efficacy and safety of adapalene and mometasone furoate combination in AA. Adapalene can be used as a new therapeutic modality in AA.

Topics: Adapalene; Administration, Cutaneous; Adolescent; Adult; Alopecia Areata; Dermatologic Agents; Drug Therapy, Combination; Female; Gels; Hair; Humans; Male; Mometasone Furoate; Patient Satisfaction; Skin Cream; Time Factors; Treatment Outcome; Young Adult

Both alopecia areata and vitiligo are common skin disorders that are considered to be caused by an autoimmune response targeted to hair follicle and melanocyte antigens, respectively. The association of these two diseases in the same patient is well known, however, coexistence of alopecia areata and vitiligo within the same lesion is very rare. Herein, we report an 8-year-old boy who had colocalization of alopecia areata and vitiligo on the frontal portion of his scalp.

Topics: Alopecia Areata; Anti-Inflammatory Agents; Child; Humans; Male; Mometasone Furoate; Pregnadienediols; Scalp Dermatoses; Vitiligo